Pascolizumab
Pascolizumab
Pascolizumab (pronunciation: pas-co-li-zu-mab) is a monoclonal antibody designed for the treatment of various cancer types. It is a type of biopharmaceutical that is developed through biological processes, rather than chemical synthesis.
Etymology
The name "Pascolizumab" is derived from the standard nomenclature for monoclonal antibodies. The suffix "-mab" is used for all these types of antibodies, while the prefix "Pasco-" does not have a specific meaning and is used for unique identification.
Function
Pascolizumab works by binding to specific proteins on the surface of cancer cells, blocking the signals that allow the cells to grow and divide. This can slow or stop the growth of the cancer, and may also make the cancer cells more susceptible to the body's immune system.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells. Pascolizumab is a type of monoclonal antibody.
- Biopharmaceutical: A type of drug produced using biotechnology. Pascolizumab is a biopharmaceutical.
- Protein: A molecule made up of amino acids that is essential for all life forms. Pascolizumab binds to specific proteins on the surface of cancer cells.
See Also
External links
- Medical encyclopedia article on Pascolizumab
- Wikipedia's article - Pascolizumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski